Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141336 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
A Phase 3 study of Seizure Disorder, Partial, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT00141336: Completed Phase 3 study of Seizure Disorder, Partial, sponsored by Pfizer.
NCT00141336 is a Phase 3 study of Seizure Disorder, Partial that has completed, run by Pfizer. The registered enrollment target is 750 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141336, a Phase 3 study of Seizure Disorder, Partial, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.
Conditions Studied
Interventions
- DRUG Pregabalin
Study Locations (20)
California
- Pfizer Investigational Site - Bakersfield
- Pfizer Investigational Site - Berkeley
- Pfizer Investigational Site - Concord
- Pfizer Investigational Site - Covina
- Pfizer Investigational Site - El Cajon
- Pfizer Investigational Site - Encino
- Pfizer Investigational Site - La Mesa
- Pfizer Investigational Site - Marina Del Ray
- Pfizer Investigational Site - Martinez
- Pfizer Investigational Site - Northridge
- Pfizer Investigational Site - Pinole
- Pfizer Investigational Site - Redondo Beach
- Pfizer Investigational Site - Sacramento
- Pfizer Investigational Site - Sacramento
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - Santa Monica
- Pfizer Investigational Site - Walnut Creek
Arizona
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Tucson
Colorado
- Pfizer Investigational Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 1999-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
What the finished NCT00141336 record still lists
NCT00141336 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 1 condition, with Seizure Disorder, Partial appearing as the primary indexed condition, and to 1 intervention - of which Pregabalin is the first listed.
NCT00141336 names 20 study sites across 3 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00141336 about?
NCT00141336 is a clinical study titled "To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.". To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.
What is the current status of trial NCT00141336?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 1999-11. Estimated completion is 2005-07.
What conditions does trial NCT00141336 study?
This clinical trial studies the following conditions: Seizure Disorder, Partial.
What interventions are being tested in trial NCT00141336?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00141336?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141336 being conducted?
This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00141336's enrollment target sits among peer trials
750 464th of 2000 higher than 1,529 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia